Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Firy Inc. (FIRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Firy Inc. — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.04 (market cap $2.81B), while Firy Inc. trades at $11.25 (market cap $185.67M). The key difference: Dyne Therapeutics Inc. Common Stock is far larger — about 15.1× Firy Inc.'s market cap, and Firy Inc. is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Firy Inc. for 13 Days on average.
| DYN | FIRY | |
|---|---|---|
Market Cap | $2.81B | $185.67M |
Volume | 2,195,902 | 194,374 |
Sector | Health | Technology |
52-Week High | $26.78 | $13.10 |
52-Week Low | $14.60 | $2.28 |
Typical Hold Time | 0 Days | 13 Days |
Enterprise Value | $2.13B | $154.27M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
FIRY trades at $12.41, up 0.16% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $31.0 million but missed EPS expectations with a net loss. Despite a $719 million legal victory against Papaya Gaming, cash burn remains high with negative operating cash flow of -$69 million in 2025. The stock shows mixed analyst sentiment with 60% hold ratings.
The outlook remains challenging with persistent losses and negative margins, though the legal win provides potential upside. Key risks include ongoing cash burn and execution uncertainty. Investors should weigh the litigation recovery potential against fundamental weakness in the core business.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →
